Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer.
Phase I studies of [N-(2-hydroxypropyl)methacrylamide] (HPMA) copolymer-doxorubicin previously showed signs of activity coupled with 5-fold decreased anthracycline toxicity in chemotherapy-refractory patients. Here we report phase II studies using a similar material (FCE28068) in patients with breas...
Váldodahkkit: | , , , , , , , , , , , , , , , , , , |
---|---|
Materiálatiipa: | Journal article |
Giella: | English |
Almmustuhtton: |
2009
|